WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
SJIF Impact Factor 8.453
Volume 14, Issue 14, 1058-1068. Review Article ISSN 2277–7105

TYPE 2 DIABETES, HEART FAILURE, AND HORMONAL DYSREGULATION: A TRIAD IN INTERNAL MEDICINE

Anto Musy Bosco J.[1]*, Dipanjan Maity[2], Sai Sowmith[3], Elisha T.[4], Shreya Rathi[5], Dr. Om Dixit[6], Kamalpreet Singh[7] and Nikita Chauhan[8]

[1*,2]Department: Pharmacy Practice, JSS College of Pharmacy, Ooty, Nilgiris.

[3]Challagiri, Master of Physiotherapy (Neurological), The Apollo University, Chittoor.

[4]Master of Physiotherapy in Orthopaedics, (MPT), The Apollo University, Chittoor.

[5,8]Amity Institute of Pharmacy, Amity University Lucknow Campus, Lucknow Uttar Pradesh.

[6]Doctor of Pharmacy, Saraswati Institute of Pharmaceutical Sciences, Gandhinagar.

[7]Doctor of Pharmacy, Ct Institute of Pharmaceutical Sciences, Jalandhar.

Article Received on
02 June 2025,

Revised on 22 June 2025,
Accepted on 12 July 2025,

DOI: 10.20959/wjpr202514-37615

***Corresponding Author**
Anto Musy Bosco J.
Department: Pharmacy practice, JSS college of Pharmacy, Ooty, Nilgiris.

ABSTRACT

This review explores the interconnections between type 2 diabetes, heart failure, and hormonal dysregulation, highlighting their complex pathophysiology and therapeutic implications. Insulin resistance, a hallmark of type 2 diabetes, is intricately linked to cardiac dysfunction through mechanisms involving oxidative stress, inflammation, and endothelial dysfunction. Hormonal dysregulation further exacerbates these effects, impacting cardiac function and contributing to heart failure. Therapeutic strategies, including pharmacological agents like SGLT2 inhibitors and lifestyle modifications, have shown promise in mitigating these risks. Future directions in diabetes management emphasize precision medicine, technological advancements, and patient-centered care to optimize outcomes. Addressing barriers to effective self-care and developing tailored interventions for special populations remain critical challenges.

KEYWORDS: Type 2 diabetes, Heart failure, Hormonal dysregulation, Insulin resistance, Cardiac dysfunction, Therapeutic interventions, Precision medicine, Patient engagement.

1. Interlinking Pathophysiology – From Insulin Resistance to Cardiac Dysfunction

Insulin resistance (IR) is a metabolic condition where the body's cells respond inadequately to insulin, a hormone critical for regulating blood sugar levels. This dysfunction not only predisposes individuals to type 2 diabetes but also has profound effects on the heart, contributing to the development of cardiac dysfunction and heart failure (HF).[1,2]

Understanding the relationship between insulin resistance and cardiac dysfunction is essential because heart failure remains a leading cause of morbidity and mortality worldwide, particularly among individuals with metabolic disorders.

The evidence consistently demonstrates that insulin resistance is intricately linked to the development and progression of cardiac dysfunction in humans. Insulin resistance contributes to myocardial impairment through multiple interrelated mechanisms. It promotes hyperinsulinemia and hyperglycemia, which induce oxidative stress, inflammation, and endothelial dysfunction within the heart muscle and vasculature. These pathological changes foster myocardial fibrosis, stiffness, and impaired relaxation, which manifest clinically as diastolic dysfunction and eventually systolic failure. This condition, often termed diabetic cardiomyopathy, occurs independently of traditional cardiovascular risk factors such as coronary artery disease or hypertension, underscoring the direct deleterious impact of insulin resistance on cardiac tissue.[2,3]

Systemic metabolic disturbances accompanying insulin resistance, including altered lipid metabolism and chronic low-grade inflammation, further exacerbate cardiac damage. Obesity, a common driver of insulin resistance, contributes to a pro-fibrotic and pro-inflammatory cardiac environment, increasing susceptibility to heart failure.[4,5] Additionally, aging and comorbidities such as chronic kidney disease amplify these effects, creating a multifactorial risk landscape for cardiac dysfunction.[5]

Clinically, surrogate markers of insulin resistance, such as the triglyceride-glucose (TyG) index and metabolic score for insulin resistance (METS-IR), have been validated as predictors of heart failure incidence and adverse outcomes in diverse populations.[6,7] Elevated TyG index values correlate with a significantly increased risk of developing heart failure and worse prognosis in patients with established HF.[1] Similarly, METS-IR shows a J-shaped association with heart failure risk, suggesting that both low and high levels of insulin resistance markers may influence cardiac outcomes.[6]

Therapeutic interventions targeting insulin resistance have shown promise in mitigating cardiac dysfunction. Pharmacologic agents such as metformin and thiazolidinediones (TZDs) improve insulin sensitivity and have demonstrated beneficial effects on heart failure-related outcomes, although evidence remains heterogeneous and further trials are warranted.[7,8]

Sodium-glucose cotransporter 2 inhibitors (SGLT2i), a newer class of antidiabetic drugs, enhance insulin sensitivity and have emerged as effective treatments for heart failure, reducing hospitalization and mortality rates in diabetic and non-diabetic patients alike. These agents not only improve glycemic control but also exert direct cardioprotective effects by modulating mitochondrial function, reducing inflammation, and improving endothelial health.[2,5,9]

Nutritional and lifestyle modifications, including caloric restriction and balanced diets tailored to body mass index, also influence insulin resistance and cardiac function. Caloric restriction in overweight heart failure patients improves myocardial efficiency and insulin sensitivity, while undernutrition poses risks in underweight individuals. The Mediterranean diet and other dietary patterns have shown mixed results, indicating the need for individualized nutritional strategies.[10,11]

At the cellular level, insulin resistance disrupts endothelial function, impairing nitric oxide availability and promoting oxidative stress, which contributes to myocardial remodeling and dysfunction.[3] The interplay between insulin resistance and endothelial dysfunction is a critical pathogenic axis in diabetic cardiomyopathy and heart failure development.[3]

Moreover, systemic aging processes exacerbate insulin resistance and cardiac decline, highlighting the complex, multifactorial nature of this relationship.[5]

2. Hormonal Dysregulation – The Endocrine Heart in Diabetes

Hormonal balance plays a crucial role in maintaining normal heart function, and disruptions in this balance—termed hormonal dysregulation—can have significant effects on the heart, especially in people with diabetes. Diabetes itself is a condition characterized by abnormal blood sugar regulation, but it also involves complex hormonal changes that affect many organs, including the heart.

The heart is not only influenced by hormones circulating in the body but also acts as an endocrine organ, producing hormones that regulate its own function and structure. Hormones

from the thyroid gland, adrenal glands, fat tissue, and the hypothalamic-pituitary axis interact with heart cells to control electrical activity and muscle performance. When these hormonal systems become dysfunctional, they can contribute to heart problems such as atrial fibrillation—a common irregular heartbeat associated with increased risk of stroke and heart failure.[12]

In diabetes, hormonal dysregulation affects the heart's ability to contract and relax properly. Experimental studies in diabetic animals have shown that diabetes reduces the heart's contractile performance, partly by impairing calcium handling within heart muscle cells, which is essential for muscle contraction. Insulin treatment can reverse some of these changes, highlighting the role of hormonal control in maintaining cardiac function. Moreover, diabetes alters the heart's response to drugs that affect heart muscle strength, indicating a complex interplay between hormonal status and cardiac pharmacology.[13]

Clinically, patients with diabetes often exhibit abnormal blood pressure patterns during sleep, known as nocturnal non-dipping, where blood pressure fails to decrease at night as it normally should. This abnormality is linked to worse cardiovascular outcomes and is associated with impaired heart rate responses and reduced physical capacity. While the exact hormonal mechanisms behind this are multifactorial and not fully understood, the presence of diabetes and its associated hormonal imbalances appear to contribute to these changes in cardiac function and blood pressure regulation.

Taken together, the evidence suggests that hormonal dysregulation in diabetes adversely impacts cardiac function by disrupting electrical signaling, muscle contraction, and blood pressure control. This can lead to structural and functional heart changes, increasing the risk of arrhythmias and heart failure. Understanding these hormonal influences is critical for developing better treatments to protect heart health in diabetic patients.[14]

3. Therapeutic Crossroads – Pharmacological and Non-Pharmacological Interventions

Diabetes mellitus, particularly type 2 diabetes, is a chronic condition characterized by elevated blood sugar levels due to insulin resistance or deficiency. Managing blood sugar, or glycemic control, is crucial to prevent complications such as cardiovascular disease, neuropathy, and cognitive decline. While medications are often prescribed, non-pharmacological interventions—such as lifestyle changes including diet, exercise, and behavioral modifications—play a foundational role in managing diabetes.

The evidence robustly supports that lifestyle modifications significantly improve glycemic control in diabetic patients. A comprehensive systematic review and meta-analysis of randomized controlled trials demonstrated that dietary interventions, especially those combining individualized counseling and group activities, reduced hemoglobin A1c (HbA1c) levels by approximately 0.5% to 1% compared to usual care.[15] HbA1c is a key marker reflecting average blood glucose over several months, and even modest reductions are clinically meaningful in reducing diabetes-related complications.

Physical activity, healthy eating, weight loss, and smoking cessation are integral components of these lifestyle interventions. A prospective cohort study involving older adults with type 2 diabetes showed that adherence to multiple healthy lifestyle factors—including no smoking, moderate alcohol use, regular exercise, balanced diet, adequate sleep, reduced sedentary time, and social engagement—was associated with a substantially lower risk of dementia, independent of glycemic control and medication use.[16] This underscores that lifestyle factors confer benefits beyond blood sugar management, improving overall health outcomes.

Nutritional quality also matters. Supplementation with polyunsaturated fatty acids (PUFAs), known for their anti-inflammatory properties, has been found to improve fasting blood glucose and insulin sensitivity in some clinical intervention studies, suggesting a potential adjunct role in glycemic management.[17] However, results are mixed, and more research is needed to clarify optimal dosing and patient populations.

Telemedicine and digital health technologies are emerging as valuable tools to support lifestyle interventions. Remote monitoring, smartphone applications, and teleconsultations facilitate self-management, medication adherence, and timely adjustments, thereby improving glycemic outcomes and reducing complications.[18] These technologies help overcome barriers such as limited access to healthcare providers and promote sustained behavioral changes.

Importantly, lifestyle interventions are not only effective but also essential for preventing or delaying the need for pharmacological treatments. Clinical guidelines emphasize initiating intensive lifestyle modification from the time of diagnosis, with medications like metformin introduced when lifestyle alone is insufficient to achieve glycemic targets.[19] This approach aims to optimize patient quality of life and minimize medication side effects.

While pharmacological agents remain necessary for many, some medications, such as sodium-glucose cotransporter-2 (SGLT2) inhibitors, carry risks like euglycemic diabetic ketoacidosis, especially in vulnerable contexts such as COVID-19 infection.[20] This highlights the importance of comprehensive management strategies where lifestyle interventions can reduce reliance on medications and their associated risks.

Finally, lifestyle modification also plays a critical role in preventing diabetes-related complications. For example, strict glycemic control combined with lifestyle changes can help prevent diabetic autonomic neuropathy, a serious but often underdiagnosed complication affecting the nervous system.[21] Moreover, managing cardiovascular risk factors through lifestyle is crucial since diabetes markedly increases the risk of stroke and heart disease.[22]

4. Future Directions and Clinical Implications in Internal Medicine

Diabetes mellitus, particularly type 2 diabetes, is a chronic condition characterized by elevated blood sugar levels due to insulin resistance or deficiency. It affects millions worldwide and is associated with serious complications such as cardiovascular disease, kidney failure, and neuropathy. The clinical management of diabetes in internal medicine is evolving rapidly, driven by advances in pharmacotherapy, technology, patient engagement strategies, and precision medicine.

One emerging future direction is the integration of precision medicine into diabetes care. Precision medicine aims to tailor diagnosis and treatment based on individual genetic, environmental, and lifestyle factors. This approach recognizes the heterogeneity of diabetes and seeks to optimize therapeutic outcomes by identifying subtypes of the disease and selecting targeted interventions accordingly.[23] While precision diagnostics are currently feasible for certain monogenic diabetes forms, ongoing research is needed to extend this to the more common complex types of diabetes.

Pharmacological innovation is another key area. New classes of drugs, especially glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and multiagonists (targeting GLP-1, glucose-dependent insulinotropic polypeptide, and glucagon receptors), have demonstrated significant benefits not only in glycemic control but also in weight management and cardiovascular risk reduction. These agents represent a shift toward therapies that address multiple metabolic pathways, offering improved patient-centered outcomes.[24]

Technological advances are increasingly shaping diabetes management. Patient-centered digital health records and mobile health applications have shown promise in enhancing disease knowledge, treatment adherence, self-management, and healthcare utilization. These tools empower patients by providing access to their health data and facilitating communication with healthcare providers. However, evidence also highlights the need for high-quality studies to confirm their long-term clinical benefits and to optimize usability, especially among patients with high disease burden.[25,26]

Continuous glucose monitoring (CGM) and decision support systems are becoming standard components of inpatient and outpatient diabetes care. Updated guidelines recommend insulin infusion protocols guided by explicit clinical decision support tools and frequent glucose monitoring to minimize hypoglycemia and optimize glycemic control in critically ill patients.[27] The future will likely see broader adoption of CGM technologies and integration with artificial intelligence to individualize glycemic targets and treatment adjustments.

Prevention strategies remain vital, particularly in individuals at high risk for developing type 2 diabetes. Metformin continues to be supported by moderate-quality evidence for delaying diabetes onset in at-risk populations, although intensive lifestyle interventions may be equally or more effective.[28] The long-term impact of pharmacologic prevention on complications and mortality requires further elucidation.

Exercise and physical activity are foundational in diabetes management. Updated consensus emphasizes regular physical activity, including aerobic, resistance, flexibility, and balance exercises, as well as reducing sedentary time to improve glycemic control and overall health.[29] Addressing barriers to exercise, including socioeconomic and health-related factors, will be essential to future clinical practice.

Patient engagement and shared decision-making are increasingly recognized as crucial for effective diabetes care. Decision aids improve patient knowledge, clarify values, reduce decisional conflict, and promote active participation in treatment choices.[30] Their use supports personalized care and may improve adherence and satisfaction without adverse effects.

Barriers to effective diabetes self-care, such as misconceptions, cultural beliefs, social stigma, limited resources, and access issues, particularly in underserved populations, remain

challenges.[31] Future directions include developing individualized and community-based interventions that address these barriers comprehensively.

In special populations, such as transplant recipients, post-transplantation diabetes mellitus (PTDM) is a significant concern. Updated international consensus emphasizes early diagnosis, risk stratification, immunosuppression modification, and incorporation of novel glucose-lowering agents tailored to this group.[32] This reflects a broader trend toward specialized management pathways for diabetes in complex clinical contexts.

Finally, ongoing research into novel pathophysiological mechanisms, such as ferroptosis and ferritinophagy in diabetes complications, may open new therapeutic avenues.[33] Understanding these molecular processes could lead to targeted interventions to prevent or mitigate diabetes-related tissue damage.

5. CONCLUSION

The interplay between type 2 diabetes, heart failure, and hormonal dysregulation underscores the multifactorial nature of these conditions, highlighting the need for comprehensive and individualized therapeutic approaches. Insulin resistance and hormonal imbalances contribute significantly to cardiac dysfunction, necessitating early intervention and holistic management strategies. Advances in pharmacotherapy, precision medicine, and digital health technologies offer new opportunities to improve patient outcomes. However, addressing barriers to effective self-care and ensuring equitable access to care remain essential for optimizing the management of type 2 diabetes and its complications. Future research should focus on elucidating novel pathophysiological mechanisms and developing targeted interventions to mitigate the burden of diabetes-related cardiovascular disease.

6. REFERENCES

1. A. Khalaji *et al.*, “Triglyceride-glucose index and heart failure: a systematic review and meta-analysis,” *Cardiovasc Diabetol*, Dec. 2023; 22(1): doi: 10.1186/s12933-023-01973-7.
2. G. Jia, A. Whaley-Connell, and J. R. Sowers, “Diabetic cardiomyopathy: a hyperglycaemia- and insulin-resistance-induced heart disease,” *Diabetologia*, Jan. 2018; 61(1): 21–28. doi: 10.1007/s00125-017-4390-4.

3. M. Wang, Y. Li, S. Li, and J. Lv, "Endothelial Dysfunction and Diabetic Cardiomyopathy.," *Front Endocrinol (Lausanne)*, Apr. 2022; 13: p. 851941. doi: 10.3389/fendo.2022.851941.
4. G. A. Balsan, J. L. Da Costa Vieira, A. M. De Oliveira, and V. L. Portal, "Relationship between adiponectin, obesity and insulin resistance," *Rev Assoc Med Bras*, Jan. 2015; 61 (1): 72–80. doi: 10.1590/1806-9282.61.01.072.
5. Z. Fang *et al.*, "Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues," *ESC Heart Fail*, Apr. 2025; 12(2): 1059–1080. doi: 10.1002/ehf2.14947.
6. X. Su, C. Zhao, and X. Zhang, "Association between METS-IR and heart failure: a cross-sectional study.," *Front Endocrinol (Lausanne)*, 2024; vol. 15: p. 1416462. doi: 10.3389/fendo.2024.1416462.
7. H. E. Lebovitz, "Thiazolidinediones: the Forgotten Diabetes Medications," *Curr Diab Rep*, Dec. 2019; 19(12): doi: 10.1007/s11892-019-1270-y.
8. P. V. Dludla *et al.*, "Metformin and heart failure–related outcomes in patients with or without diabetes: a systematic review of randomized controlled trials," *Heart Fail Rev.*, Nov. 2021; 26(6): 1437–1445. doi: 10.1007/s10741-020-09942-y.
9. M. Fakhrolmobasheri *et al.*, "Effect of sodium–glucose cotransporter 2 inhibitors on insulin resistance; a systematic review and meta-analysis," *Acta Diabetol*, Feb. 2023; 60(2): 191–202, doi: 10.1007/s00592-022-01981-1.
10. V. E. Bianchi, "Nutrition in chronic heart failure patients: a systematic review," *Heart Fail Rev.*, Nov. 2020; 25(6): 1017–1026, doi: 10.1007/s10741-019-09891-1.
11. V. E. Bianchi, "Caloric restriction in heart failure: A systematic review," *Clin Nutr ESPEN*, Aug. 2020; vol. 38: 50–60. doi: 10.1016/j.clnesp.2020.04.009.
12. M. Aguilar, R. A. Rose, A. Takawale, S. Nattel, and S. Reilly, "New aspects of endocrine control of atrial fibrillation and possibilities for clinical translation.," *Cardiovasc Res.*, Jun. 2021; 117(7): 1645–1661. doi: 10.1093/cvr/cvab080.
13. J. H. McNeill, "1983 Upjohn Award lecture. Endocrine dysfunction and cardiac performance.," *Can J Physiol Pharmacol*, Jan. 1985; 63(1): 1–8. doi: 10.1139/y85-001.
14. P. Ritvo *et al.*, "Functional capacity and heart rate response: associations with nocturnal hypertension.," *BMC Cardiovasc Disord*, Jul. 2015; 15: 74. doi: 10.1186/s12872-015-0064-7.
15. L. García-Molina, A. M. Lewis-Mikhael, B. Riquelme-Gallego, N. Cano-Ibáñez, M. J. Oliveras-López, and A. Bueno-Cavanillas, "Improving type 2 diabetes mellitus glycaemic control through lifestyle modification implementing diet intervention: a systematic review

and meta-analysis," *Eur J Nutr*,, Jun. 2020; 59(4): 1313–1328. doi: 10.1007/s00394-019-02147-6.

16. B. Wang, N. Wang, Y. Sun, X. Tan, J. Zhang, and Y. Lu, "Association of Combined Healthy Lifestyle Factors with Incident Dementia in Patients with Type 2 Diabetes," *Neurology*, Nov. 2022; 99(21): E2336–E2345. doi: 10.1212/WNL.0000000000201231.
17. O. G. L. Coelho, B. P. da Silva, D. M. U. P. Rocha, L. L. Lopes, and R. de C. G. Alfenas, "Polyunsaturated fatty acids and type 2 diabetes: Impact on the glycemic control mechanism," *Crit Rev Food Sci Nutr*, Nov, 2017; 57(17): 3614–3619. doi: 10.1080/10408398.2015.1130016.
18. J. Kesavadev and V. Mohan, "Reducing the Cost of Diabetes Care with Telemedicine, Smartphone, and Home Monitoring.," *J Indian Inst Sci*, Apr, 2023; 103(1): 1–12. doi: 10.1007/s41745-023-00363-y.
19. S. Y. Rhee *et al.*, "Monotherapy in patients with type 2 diabetes mellitus," *Korean J Intern Med.*, Nov. 2017; 32(6): 959–966. doi: 10.3904/kjim.2017.312.
20. A. Khedr *et al.*, "Sodium-glucose cotransporter-2 inhibitor-associated euglycemic diabetic ketoacidosis in COVID-19-infected patients: A systematic review of case reports.," *World J Clin Cases*, Aug, 2023 11(24): 5700–5709. doi: 10.12998/wjcc.v11.i24.5700.
21. A. Verrotti, G. Prezioso, R. Scattoni, and F. Chiarelli, "Autonomic neuropathy in diabetes mellitus," *Front Endocrinol (Lausanne)*, Dec, 2014; vol. 5, no: doi: 10.3389/fendo.2014.00205.
22. M. S. Phipps, A. M. Jastreboff, K. Furie, and W. N. Kernan, "The diagnosis and management of cerebrovascular disease in diabetes," *Curr Diab Rep.*, Jun, 2012; 12(3): 314–323. doi: 10.1007/s11892-012-0271-x.
23. W. K. Chung *et al.*, "Precision medicine in diabetes: a Consensus Report from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)," *Diabetologia*, Sep. 2020; 63(9): 1671–1693. doi: 10.1007/s00125-020-05181-w.
24. J. W. Son and S. Lim, "Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management," *Endocrinology and Metabolism*, Apr. 2024; 39(2): 206–221. doi: 10.3803/EnM.2024.1940.
25. K. Tabi *et al.*, "Mobile apps for medication management: Review and analysis," *JMIR Mhealth Uhealth*, 2019; 7(9): doi: 10.2196/13608.

26. M. R. Brands, S. C. Gouw, M. Beestrum, R. M. Cronin, K. Fijnvandraat, and S. M. Badawy, "Patient-Centered Digital Health Records and Their Effects on Health Outcomes: Systematic Review," *J Med Internet Res.*, Dec. 2022; 24(12): doi: 10.2196/43086.
27. K. Honarmand *et al.*, "Society of Critical Care Medicine Guidelines on Glycemic Control for Critically Ill Children and Adults 2024," *Crit Care Med.*, Apr. 2024; 52(4): E161–E181. doi: 10.1097/CCM.0000000000006174.
28. K. S. Madsen, Y. Chi, M. I. Metzendorf, B. Richter, and B. Hemmingsen, "Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus," *Cochrane Database of Systematic Reviews*, Dec. 2019; 2019(12): doi: 10.1002/14651858.CD008558.pub2.
29. J. A. Kanaley *et al.*, "Exercise/Physical Activity in Individuals with Type 2 Diabetes: A Consensus Statement from the American College of Sports Medicine," *Med Sci Sports Exerc*, Feb. 2022; 54(2): 353–368. doi: 10.1249/MSS.0000000000002800.
30. D. Stacey *et al.*, "Decision aids for people facing health treatment or screening decisions," *Cochrane Database of Systematic Reviews*, Apr. 2017; 2017(4): doi: 10.1002/14651858.CD001431.pub5.
31. V. Mogre, N. A. Johnson, F. Tzelepis, and C. Paul, "Barriers to diabetic self-care: A qualitative study of patients' and healthcare providers' perspectives," *J Clin Nurs*, Jun. 2019; 28(11–12): 2296–2308. doi: 10.1111/jocn.14835.
32. A. Sharif *et al.*, "International consensus on post-transplantation diabetes mellitus," *Nephrology Dialysis Transplantation*, Mar, 2024; 39(3): 531–549. doi: 10.1093/ndt/gfad258.
33. J. He *et al.*, "Ferroptosis and ferritinophagy in diabetes complications," *Mol Metab*, Jun. 2022; vol. 60: doi: 10.1016/j.molmet.2022.101470.